Clinical Data BMS brings the buzz around late-stage readouts amid a so-so Q1 Pharmaceutical TechnologyBMS is awaiting Phase III readouts from potential Eliquis successor, milvexian and schizophrenia med, Cobenfy, expected later this year.Read full story pharminent May 1, 2026 (Last updated: May 1, 2026) Pharmaceutical Technology BMS is awaiting Phase III readouts from potential Eliquis successor, milvexian and schizophrenia med, Cobenfy, expected later this year. Read full story Post navigation Previous: Where Gross-to-net Pressure Actually Lives After LaunchNext: Eli Lilly lifts 2026 revenue guidance as Q1 marks dominant opening Related Stories Clinical Data Novo Nordisk starts trialing lower maintenance doses of oral Wegovy pharminent August 21, 2026 Clinical Data Cancer vaccine win restores Wall Street’s faith in Moderna pharminent August 20, 2026 Clinical Data New Taiho, Cullian data heats up lung cancer drug battle pharminent August 13, 2026
